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Ross Lawrenson
Colorectal cancer (CRC) is the second most common cancer in New Zealand.1 Almost 3,500 new cases were regis-
tered in New Zealand in 2018, with around 
1,200 deaths.2 The incidence of CRC in New 
Zealand is high by international standards; 
the GLOBOCAN age-standardised estimated 
incidence rate shows Australia and New Zea-
land as having the highest rates of CRC in the 
world.2 Outcomes in New Zealand are poor; 
fi ve-year survival rates in New Zealand 
following a CRC diagnosis are lower than 
Australia.3–5 Stage of disease at diagnosis, 
Māori ethnicity, deprivation level and rate of 
presentation to hospital emergency depart-
ments5,6 are contributing factors associated 
with poorer outcomes.
Worldwide, a higher incidence of CRC 
occurs in those aged 70 years or more.7–9 
Increasing levels of comorbidity7,10–13 
together with higher risk of functional and 
cognitive impairment12 contribute to poorer 
outcomes for elderly compared to younger 
patients. Higher rates of comorbidity and 
increasing frailty results in older patients 
being less likely to access treatment,11,14–16 
ABSTRACT 
AIM: The incidence of colorectal cancer (CRC) in New Zealand is high by international standards. 
Approximately 1,200 people in New Zealand die from this disease per year. Outcomes in New Zealand 
following a CRC diagnosis are poor. We aimed to describe the characteristics and outcomes of patients 
diagnosed with CRC across the four regional cancer networks in New Zealand. 
METHOD: Patient demographics, tumour characteristics and survival outcomes for all patients diagnosed 
with CRC between 2006 and 2015 were analysed retrospectively from the National Cancer Registry (NZCR) 
and National Mortality collection and were linked by National Health Index (NHI) number. 
RESULTS: A total of 29,221 CRC cases were recorded during the 10-year study period, of which the majority 
were cancer of the colon (67.9%). In this sample, 42.0% were >75 years, 52.1% were male and 88.1% were 
New Zealand European. A er adjustment for factors such as age, gender, ethnicity year of diagnosis, 
cancer extent, cancer grade, lymph node and cancer site, cancer-related and all-cause survival were not 
significantly di erent by cancer network for those aged <75 but for patients aged >75 years, those living 
in the Central and Midland Cancer Network had a higher risk of dying of CRC compared to those in the 
Northern Cancer Network (1.12, 95% CI: 1.03–1.22 and 1.10, 95% CI: 1.02–1.18 respectively). Overall, Māori 
and Pacific people had worse cancer-specific and all-cause survival than New Zealand European. 
CONCLUSION: No regional variations were seen within New Zealand for the characteristics and survival 
outcomes of patients <75 diagnosed with CRC. The risk of dying from CRC increased for those >75, which is 
supportive of the international literature regarding outcomes for the elderly and CRC. We continue to show 
disparity in outcomes for Māori and Pacific patients diagnosed with CRC in New Zealand. 
ARTICLE
43 NZMJ 24 April 2020, Vol 133 No 1513ISSN 1175-8716                 © NZMA
www.nzma.org.nz/journal
have higher rates of emergency surgery 
and have signifi cant risk of mortality at 
90 days post-surgery.17 An assessment 
of cancer survival in seven high-income 
countries from 1995–2014 demonstrated 
an increase in age standardised fi ve-year 
net survival in New Zealand for both colon 
and rectal cancer in those aged <75, but a 
decrease for those aged >75 diagnosed with 
colon cancer.18 Thus, New Zealand data are 
supportive of the international literature, 
where poor survival is noted with increasing 
age, particularly for those aged 80 and 
over8,16,19 with little improvement over time 
despite advances in treatment options. 
New Zealand is divided into four regional 
cancer networks: the Northern, Midland, 
Central and Southern Cancer Networks. 
Within these regional networks are several 
district health boards (DHBs) that provide 
for the health needs of the local population: 
the Northern Cancer Network covers the 
Northland, Auckland, Counties Manukau 
and Waitemata DHBs, the Midland Cancer 
Network covers Waikato, Lakes, Bay of 
Plenty and Tairawhiti, and the Central 
Cancer Network encompasses Taranaki, 
Whanganui, MidCentral, Hawke’s Bay, Wair-
arapa, Hutt Valley and Capital and Coast 
DHBs. The Southern Cancer Network encom-
passes the whole of the South Island. This 
study aimed to quantify the outcomes of 
patients diagnosed with CRC in New Zealand 
using national databases across these four 
regional networks. 
Method
This study retrospectively reviewed 
patients diagnosed with CRC (ICD-10-AM 
codes C18–C20) in New Zealand between 
01 January 2006 and 31 December 2015. 
Eligible patients were identifi ed from the 
New Zealand Cancer Registry (NZCR). Their 
mortality information was obtained from 
the Mortality Collection and linked by 
National Health Index (NHI) number. 
The combined dataset consisted of: 1) 
patient demographics: date of birth, gender, 
ethnicity and district health board (DHB); 
2) tumour characteristics: date of diagnosis, 
cancer site, cancer extent and number of 
positive lymph nodes; and 3) date of death 
and cause of death. Age at diagnosis was 
categorised into fi ve groups: <55, 55–64, 
65–74, 75–84 and 85+ years. Ethnicity was 
classifi ed into New Zealand European, Māori, 
Pacifi c, Asian and others as recorded on the 
NZCR using prioritisation to manage multiple 
ethnicities. Patients were grouped into one 
of the four cancer networks based on their 
domicile: Central, Midland, Northern or 
Southern Cancer Network. The NZCR records 
cancer stage and uses both the Tumour Node 
Metastases (TNM) staging system20 and the 
Surveillance Epidemiology and End Results 
(SEER) programme of cancer staging defi ni-
tions.21 Complete SEER staging was recorded 
for 81% of CRC patients. 
Patient and tumour characteristics were 
compared between the four cancer networks 
and the differences were examined with 
Chi-square tests. Patients were considered 
to be censored on the date of death or the 
last updated date of Mortality Collection, 
which was 31 December 2015. Survival 
analyses were stratifi ed by patients aged less 
than 75 years and patients aged 75 years or 
over. The Kaplan-Meier method was used 
to estimate the colorectal cancer-specifi c 
survival and all-cause survival by cancer 
network. A Cox proportional hazards 
model was used to estimate the hazard 
ratios of colorectal cancer-specifi c survival 
and all-cause survival by cancer network 
after adjustment for ethnicity, gender, 
year of diagnosis, cancer extent, cancer 
grade, lymph node and cancer site. All 
data analyses were performed in IBM SPSS 
statistics 25 (New York, US). The study was 
approved by the Health and Disability Ethics 
Committee (HDEC) –17/NTB/156.
Results
Patient and tumour characteristics by 
cancer network are shown in Table 1. In the 
10-year period, 2006–2015, 29,221 people 
were diagnosed with CRC in New Zealand. 
Of these, 52.1% of patients were male. 
Overall, 88.1% were New Zealand European 
and only 5.4% were Māori. The Midland 
Cancer Network had the highest proportion 
of Māori patients (8.7% vs 2.7–6.0%), the 
Northern Cancer Network had the highest 
proportion of Asian (6.6% vs 1.0–2.0%) and 
Pacifi c patients (4.8% vs 0.3–1.7%), while 
the Southern Cancer Network was 95% New 
Zealand European. Patients in the Central 
and the Midland Cancer Network were 
younger and less likely to be diagnosed at 
age >75 years (33.3% and 34.0%, p<0.001) 
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Table 1: Patient and tumour characteristics by Cancer Network.
Characteristics Central Midland Northern Southern P-value Unknown Total
Gender
Female 2,778 48.6% 2,886 47.8% 4,112 46.8% 4,201 48.7% 0.065 25 43.1% 14,002 47.9%
Male 2,941 51.4% 3,156 52.2% 4,665 53.2% 4,424 51.3% 33 56.9% 15,219 52.1%
Ethnicity <0.001
Asian 116 2.0% 67 1.1% 575 6.6% 83 1.0% 3 5.2% 844 2.9%
European 5,078 88.8% 5,336 88.3% 7,093 80.8% 8,205 95.1% 39 67.2% 25,751 88.1%
Māori 344 6.0% 523 8.7% 493 5.6% 229 2.7% 1 1.7% 1,590 5.4%
Pacific 99 1.7% 31 0.5% 421 4.8% 29 0.3% 10 17.2% 451 1.5%
Others 82 1.4% 85 1.4% 195 2.2% 79 0.9% 5 8.6% 585 2.0%
Age group <0.001
<55 669 11.7% 644 10.7% 1,169 13.3% 838 9.7% 12 20.7% 3,332 11.4%
55–64 929 16.2% 947 15.7% 1,591 18.1% 1,460 16.9% 18 31.0% 4,945 16.9%
65–74 1,644 28.7% 1,795 29.7% 2,534 28.9% 2,735 31.7% 17 29.3% 8,725 29.9%
75–84 1,743 30.5% 1,946 32.2% 2,446 27.9% 2,576 29.9% 9 15.5% 8,720 29.8%
85+ 734 12.8% 710 11.8% 1,037 11.8% 1,016 11.8% 2 3.4% 3,499 12.0%
Cancer site <0.001
C18 3,884 67.9% 4,191 69.4% 5,810 66.2% 5,919 68.6% 40 69.0% 19,844 67.9%
C19 336 5.9% 411 6.8% 699 8.0% 562 6.5% 2 3.4% 2,010 6.9%
C20 1,499 26.2% 1,440 23.8% 2,268 25.8% 2,144 24.9% 16 27.6% 7,367 25.2%
Extent <0.001
B 1,261 28.2% 1,544 30.7% 2,122 29.6% 1,997 28.2% 9 19.1% 6,933 29.1%
C 778 17.4% 801 15.9% 1,307 18.2% 1,281 18.1% 10 21.3% 4,177 17.5%
D 1,291 28.9% 1,476 29.3% 2,075 28.9% 1,996 28.2% 15 31.9% 6,853 28.8%
E 1,141 25.5% 1,216 24.1% 1,677 23.4% 1,816 25.6% 13 27.7% 5,863 24.6%
F 1,248 1,005 1,596 1,535 11 5,395
Grade <0.001
1 238 5.0% 577 11.4% 1,317 19.0% 460 7.0% 9 20.9% 2,601 11.1%
2 3,610 75.7% 3,503 69.2% 4,550 65.6% 4,517 68.7% 27 62.8% 16,207 69.3%
3 861 18.1% 896 17.7% 852 12.3% 1,524 23.2% 6 14.0% 4,139 17.7%
4 59 1.2% 88 1.7% 215 3.1% 75 1.1% 1 2.3% 438 1.9%
Unknown 951 978 1,843 2,049 15 5,836
Lymph nodes 0.115
No positive nodes 1,964 55.9% 2,206 56.8% 3,212 57.4% 3,232 58.4% 20 52.6% 10,634 57.3%
Positive nodes 1,549 44.1% 1,678 43.2% 2,381 42.6% 2,303 41.6% 18 47.4% 7,929 42.7%
Unknown 2,206 2,158 3,184 3,090 20 10,658
Total 5,719   6,042   8,777   8,625   58   29,221  
C18: Malignant neoplasm of colon, 
C19: Malignant neoplasm of rectosigmoid junction
C20: Malignant neoplasm of rectum
Extent
B: Localised to organ of origin
C: Invasion of adjacent tissue or organ
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Figure 1: Colorectal cancer-specifi c survival by cancer network: (a) <75 years (p=0.000); (b) ≥75 years 
(p=0.005).
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Figure 2: All-cause survival by cancer network: (a) <75 years (p=0.000); (b) ≥75 years (p=0.114).
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Table 2: Hazard ratios for cancer-specifi c mortality and all-cause mortality for patients aged <75.
Cancer-specific mortality All-cause mortality
Factors p-value Hazard 
ratio
95% CI p-value Hazard 
ratio
95% CI
Lower Upper Lower Upper
Age (continuous) <0.001 1.02 1.01 1.02 <0.001 1.02 1.02 1.03
Ethnicity
European Ref Ref
Māori <0.001 1.30 1.18 1.43 <0.001 1.41 1.30 1.54
Pacific 0.170 1.12 0.95 1.31 0.027 1.18 1.02 1.37
Asian 0.001 0.73 0.60 0.88 <0.001 0.69 0.58 0.83
Others <0.001 0.35 0.25 0.49 <0.001 0.30 0.22 0.42
Gender
Female Ref Ref
Male 0.003 1.09 1.03 1.16 <0.001 1.13 1.07 1.19
Year (continuous) <0.001 0.94 0.93 0.95 <0.001 0.95 0.94 0.96
Cancer Network
Central 0.330 1.04 0.96 1.13 0.082 1.07 0.99 1.16
Midland 0.452 1.03 0.95 1.12 0.306 1.04 0.96 1.12
Northern Ref Ref
Southern 0.052 0.93 0.86 1.00 0.147 0.95 0.89 1.02
Extent
B Ref Ref
C <0.001 2.92 2.43 3.52 <0.001 1.75 1.53 2.00
D <0.001 4.46 3.74 5.31 <0.001 2.42 2.11 2.77
E <0.001 21.84 18.67 25.55 <0.001 10.83 9.67 12.12
Grade
1 Ref Ref
2 0.011 1.17 1.04 1.33 0.028 1.13 1.01 1.26
3 <0.001 2.16 1.90 2.46 <0.001 1.96 1.75 2.20
4 0.008 1.57 1.12 2.21 0.002 1.60 1.18 2.16
Lymph node
No positive nodes Ref Ref
Positive nodes <0.001 1.69 1.48 1.93 <0.001 1.45 1.29 1.63
Cancer site
C18 Ref Ref
C19 0.043 0.90 0.81 1.00 0.043 0.91 0.83 1.00
C20 <0.001 0.71 0.66 0.77 <0.001 0.71 0.67 0.77
C18: Malignant neoplasm of colon, 
C19: Malignant neoplasm of rectosigmoid junction
C20: Malignant neoplasm of rectum
Extent
B: Localised to organ of origin
C: Invasion of adjacent tissue or organ
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Table 3: Hazard ratios for cancer-specifi c mortality and all-cause mortality for patients aged ≥75 years.
Cancer-specific mortality All-cause mortality
Factors p-value Hazard 
ratio
95% CI p-value Hazard 
ratio
95% CI
Lower Upper Lower Upper
Age (continuous) <0.001 1.04 1.04 1.05 <0.001 1.06 1.05 1.06
Ethnicity 
European Ref       Ref      
Māori 0.564 1.06 0.88 1.27 <0.001 1.29 1.12 1.49
Pacific 0.026 1.35 1.04 1.75 0.020 1.32 1.04 1.66
Asian 0.030 0.76 0.60 0.97 0.011 0.77 0.63 0.94
Others 0.001 0.45 0.27 0.73 <0.001 0.36 0.23 0.55
Gender
Female Ref       Ref      
Male 0.572 1.02 0.96 1.08 <0.001 1.12 1.06 1.17
Year (continuous) <0.001 0.96 0.95 0.97 <0.001 0.97 0.96 0.98
Cancer Network
Central 0.006 1.12 1.03 1.22 0.016 1.09 1.02 1.17
Midland 0.098 1.07 0.99 1.17 0.008 1.10 1.02 1.18
Northern Ref Ref
Southern 0.892 1.01 0.93 1.09 0.256 1.04 0.97 1.11
Extent
B Ref       Ref      
C <0.001 2.46 2.10 2.88 <0.001 1.39 1.26 1.53
D <0.001 3.81 3.19 4.55 <0.001 1.99 1.75 2.27
E <0.001 13.18 11.32 15.36 <0.001 5.81 5.24 6.43
Grade
1 Ref       Ref      
2 <0.001 1.33 1.15 1.54 0.002 1.17 1.06 1.30
3 <0.001 1.94 1.66 2.26 <0.001 1.56 1.39 1.75
4 <0.001 1.94 1.47 2.56 0.002 1.48 1.16 1.89
Lymph node
No positive nodes Ref       Ref      
Positive nodes <0.001 1.42 1.22 1.65 0.030 1.14 1.01 1.29
Cancer site
C18 Ref       Ref      
C19 0.136 0.91 0.80 1.03 0.046 0.90 0.81 1.00
C20 <0.001 0.80 0.73 0.86 <0.001 0.78 0.73 0.83
C18: Malignant neoplasm of colon, 
C19: Malignant neoplasm of rectosigmoid junction
C20: Malignant neoplasm of rectum
Extent
B: Localised to organ of origin
C: Invasion of adjacent tissue or organ
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than patients in the Northern and Southern 
Cancer Network (39.7% and 41.7%, p<0.001). 
Patients in the Central Cancer Network 
were more likely to have rectal cancer 
(C20: 26.2% vs 23.8–25.8%, p<0.001) than 
the other cancer networks. Patients in the 
Northern Cancer Network had more grade 
1 cancer (19.0% vs 5.0–11.4%), but more 
grade 4 cancer (3.1% vs 1.1–1.7%) than other 
regions (p<0.001). The proportion of patients 
reporting positive lymph nodes were similar 
across the four cancer networks. 
The observed regional difference in 
survival was greater in patients under 75 
years than in patients aged 75 years or older 
(Figures 1 and 2). Patients aged less than 75 
years in the Northern Cancer Network had 
the best survival: fi ve-year cancer-specifi c 
survival of 69.2% (67.7–70.6%) and fi ve-year 
all-cause survival of 64.9% (63.4–66.3%); 
while their counterparts in the Midland 
Cancer Network had the worst survival: 
fi ve-year cancer-specifi c survival of 62.9% 
(61.0–64.8%) and fi ve-year all-cause survival 
of 58.3% (56.4–60.2%). For patients aged 
75 years or older, the fi ve-year all-cause 
survival between the four cancer networks 
was similar (p=0.114) (Figure 2B) while there 
were small differences in cancer-specifi c 
survival between regions (Figure 1B). 
Cancer-specifi c survival and all-cause 
survival improved over time for both 
patients under 75 years and patients aged 
75 years or older, after adjustment for other 
factors (Tables 2 and 3). The risk of dying 
of CRC and the risk of dying from other 
causes both increased with age. Men under 
75 years were more likely to die of CRC 
compared to women, but men aged 75 years 
or older had a similar risk. For patients 
aged under 75 years, Māori had the highest 
hazard ratio of cancer-specifi c mortality 
(1.30, 95% CI: 1.18–1.43) and the highest 
hazard ratio of all-cause mortality (1.41, 95% 
CI: 1.30–1.54) compared to New Zealand 
European (Table 2). However, for patients 
age 75 years or older, Pacifi c patients had 
the highest hazard ratio of cancer-specifi c 
mortality (1.35, 95% CI: 1.04–1.75) and the 
highest hazard ratio of all-cause mortality 
(1.32, 95% CI: 1.04–1.66) compared to 
New Zealand European (Table 3). After 
adjustment in a multivariate analysis for 
other factors (age, ethnicity, gender, year 
of diagnosis, cancer extent, cancer grade, 
lymph node and cancer site), the differences 
in the cancer-specifi c mortality and all-cause 
mortality for patients aged less than 75 
years between the four cancer networks 
disappeared. However, for patients aged 75 
years or older, those resident in the Central 
and Midland Cancer Network had a higher 
risk of dying of CRC compared to patients in 
the Northern Cancer Network (1.12, 95% CI: 
1.03–1.22 and 1.10, 95% CI: 1.02–1.18 respec-
tively). For both cancer-specifi c mortality 
and all-cause mortality for patients under 
75 years and patients aged 75 years or older, 
the risk was higher in patients with colon 
cancer, patients with more extensive cancer, 
patients with higher grade of cancer and 
patients with positive lymph nodes.
Discussion
New Zealand has high rates of CRC, and 
poorer outcomes compared to International 
Cancer Benchmarking Partnership (ICPB) 
and GLOBOCAN data.2,18 After adjustment 
for patient and tumour factors, there 
was no signifi cant difference in survival 
between regions for those aged <75, but for 
those aged >75 there were small regional 
differences. 
Cancer-specifi c and all-cause mortality 
increased with age. Poor CRC survival with 
increasing age has been reported inter-
nationally,8,16,19 and is attributed to higher 
levels of functional limitation12 and multi-co-
morbidity in older patients.7,10,11 Patients 
aged <75 and living in the Northern Cancer 
Network had the best fi ve-year all cause and 
cancer-specifi c survival, and patients living 
in the Midland Cancer Network had the 
worst. However, after adjustment for patient 
and tumour-related factors these regional 
variations were no longer important. One 
important factor was that although Māori 
only account for 5.4% of cases, outcomes for 
Māori are poor, with an unadjusted HR for 
cancer-specifi c survival of 1.3 and all-cause 
survival of 1.41 in patients <75. The Midland 
region had the highest proportion of Māori 
and this may account for some of the 
disparity in outcomes. Another factor was 
tumour characteristics. The Midland region 
also had a greater proportion of colon cases. 
Cancer-specifi c outcomes for rectal cancer 
were 20% better than outcomes for colon 
cancer. Thus after adjustment for a number 
of patient and tumour factors, including 
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ethnicity and tumour location, we can see 
that the impact of the health services in 
each region seems to result in equitable 
outcomes, especially for those <75. 
Māori and Pacifi c patients <75 had worse 
all-cause and cancer-specifi c survival than 
New Zealand European. Historically, Māori 
have a lower incidence of CRC compared 
to New Zealand European,22–24 but this 
incidence has been rising.5 Our data are 
consistent with poorer health outcomes 
often observed in Māori and Pacifi c cancer 
patients in New Zealand6,25–28 and is in 
line with reported survival rates of indig-
enous and ethnic minority populations 
in other countries.23,29–32 Of interest was 
the fi nding that in the over 75 year age 
group, while Pacifi c patients had poorer 
survival (OR 1.35) compared with New 
Zealand European, outcomes for Māori 
were similar (OR 1.06). Factors contrib-
uting to the ethnic disparities seen in New 
Zealand cancer care are well documented; 
Māori experience more inequalities/
barriers when accessing health services 
than non-Māori,27,28 experience a lower level 
of care from those services26 and do not 
get the same access to treatment.33 Māori 
and Pacifi c patients are also more likely 
to present with metastatic disease,6,28,34,35 
experience delays to diagnosis6 and present 
to the emergency department compared to 
non-Māori /non-Pacifi c patients.6 Disease 
biology and culture (eg, diet, help-seeking 
behaviour),27 deprivation level,6 and 
higher levels of comorbidity for Māori and 
Pacifi c patients6,28,31,33,36 are also factors that 
contribute to these disparities. 
Strengths/limitations
The New Zealand Cancer Registry (NZCR) 
is a large, population-based register of 
all cancer registrations in New Zealand. 
Accuracy of the demographic data in the 
NZCR is high.37 Combining with data from 
the Mortality Collection increases the 
robustness of the dataset used. However, 
a limitation of this study was that we 
were unable to access surgical and other 
treatment data, which was missing from the 
dataset. It would be worthwhile to evaluate 
whether CRC outcomes also differ with 
regard to treatment in future studies. 
Conclusions
No regional variations were seen within 
New Zealand for the characteristics and 
survival outcomes of patients <75 diag-
nosed with CRC. However, the risk of dying 
from CRC increased for those >75, which is 
supportive of the international literature 
regarding outcomes for elderly patients. We 
continue to show disparity in outcomes for 
Māori and Pacifi c patients diagnosed with 
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